Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:26:29 EDT Fri 10 May 2024
Enter Symbol
or Name
USA
CA



Q:ATRA - ATARA BIOTHERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATRA - Q0.40.5288·0.59950.10.5299-0.0159-2.92,056.91,0192,3530.57  0.6283  0.5252.535  0.198619:59:43May 0915 min RT 2¢

Recent Trades - Last 10 of 2353
Time ETExPriceChangeVolume
19:59:43Q0.5301-0.0157661
19:56:37Q0.5399-0.0059100
19:54:29Q0.5301-0.01579
18:52:33Q0.545-0.00081,214
18:40:30Q0.5720.02621
17:50:35Q0.60210.0563100
17:36:48Q0.55350.0077135
17:21:46Q0.55470.0089100
16:40:13Q0.5389-0.0069600
16:39:59Q0.5389-0.00691

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-09 16:01U:ATRANews ReleaseAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
2024-05-03 16:01U:ATRANews ReleaseAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-04-05 16:01U:ATRANews ReleaseAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-28 08:30U:ATRANews ReleaseAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
2024-02-29 09:05U:ATRANews ReleaseAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
2024-02-28 16:30U:ATRANews ReleaseAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
2024-02-14 09:00U:ATRANews ReleaseAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
2024-01-31 18:30U:ATRANews ReleaseAtara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel ‚ ® Data in The Lancet Oncology
2024-01-08 09:00U:ATRANews ReleaseAtara Biotherapeutics Announces $15 Million Registered Direct Offering
2024-01-08 08:00U:ATRANews ReleaseAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-04 16:01U:ATRANews ReleaseAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 16:01U:ATRANews ReleaseAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel ‚ ® Partnership with Pierre Fabre Laboratories
2023-12-11 12:00U:ATRANews ReleaseAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
2023-12-01 16:01U:ATRANews ReleaseAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 18:05U:ATRANews ReleaseAtara Biotherapeutics To Present Positive New Tab-cel ‚ ® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
2023-11-22 16:01U:ATRANews ReleaseAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-10 16:01U:ATRANews ReleaseAtara Biotherapeutics To Participate at the Stifel Healthcare Conference
2023-11-08 17:35U:ATRANews ReleaseAtara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
2023-11-01 08:30U:ATRANews ReleaseAtara Biotherapeutics Announces Expanded Global Tab-cel ‚ ® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
2023-10-06 16:01U:ATRANews ReleaseAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)